Source: Annual Congress 2006 - Update on treatment of COPD II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. W. Dal Negro, M. Visconti, C. Micheletto, S. Tognella (Bussolengo, Italy). Anti-oxidant effects of erdosteine in current smokers with mild COPD. Eur Respir J 2006; 28: Suppl. 50, 2507

Member's Comments

No comment yet.

Related content which might interest you: The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Long-term use of antioxidant mucolytic erdosteine is especially beneficial in patients with more severe COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Effect of erdosteine in moderately severe COPD patients Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 The effect of long-term treatment with erdosteine on moderate or severe COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Efficacy of roflumilast in former and current smokers with COPD Source: Annual Congress 2011 - COPD management Year: 2011 Airway and systemic inflammation profile in current smokers controls, COPD current smokers and COPD ex-smokers Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Comparative effectiveness of add-on omalizumab for the treatment of severe persistent asthma between current and former smokers vs. non-smokers Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Effect of suplementary dietary antioxidants in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006 Acute effect of smoking in normal and asthmatic smokers Source: Annual Congress 2008 - Asthma: growing understanding of influential factors Year: 2008 Effects of smoking cessation on spirometry in mild to moderate COPD Source: Virtual Congress 2020 – Smoking disease landscape: from inflammation to lung function and comorbidities Year: 2020 N-acetylcysteine for the treatment of acute exacerbations of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002 Budesonide/formoterol significantly improves lung function and reduces exacerbations in both smokers and ex-smokers with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Effects of high dose N-acetylcysteine in COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Antitussive and antiinflammatory effect of montelukast in patients with cough variant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Prulifloxacin in the treatment of acute exacerbations of COPD (AECOPD) in cigarette smokers Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008 Effect of one moderate or mild exacerbation on lung function and serum inflammatory markers in ex smokers patients with COPD Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients Year: 2009 Restoring corticosteroid sensitivity in COPD and smokers with asthma Source: Annual Congress 2008 - Smokers with asthma versus COPD: differences and similarities Year: 2008 Anti-inflammatory effects of targeted lung denervation in patients with COPD Source: Eur Respir J 2015; 46: 1489-1492 Year: 2015 Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009